Particle.news
Download on the App Store

Withings Introduces Body Scan 2, a Home Scale Claiming 60+ Biomarkers in 90 Seconds

Withings targets a Q2 2026 EU launch at €499.95 pending CE clearance.

Overview

  • The device combines impedance cardiography with a 6‑lead ECG to assess cardiac performance and detect arrhythmias such as atrial fibrillation.
  • It measures pulse wave velocity to gauge arterial stiffness and uses ultra‑high‑frequency bioimpedance spectroscopy to estimate cell health and metabolic efficiency.
  • Withings says AI models provide warnings and recommendations, including a notification for elevated hypertension risk without a cuff or blood sample.
  • Results sync over Wi‑Fi or Bluetooth to the Withings app, which aggregates metrics into a long‑term health score, and the company cites GDPR/HIPAA compliance plus ISO 27001/27701 certifications.
  • Body Scan 2 includes a handle with an LCD display and a rechargeable battery rated up to 15 months, and availability depends on CE approval for its measurement functions.